Defective T-lymphocyte chemotactic factor production in patients with established malignancy.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Clinical Immunology and Immunopathology

• Publication date

  1986-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0090-1229(86)90139-XPMID 2934199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes.

  1984cited by this paper
• Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population.

  1984cited by this paper
• Suppressor cells in melanoma and lung cancer: correlation with the clinical stage.

  1983cited by this paper
• Lymphocyte subsets involved in tumor-activated nonspecific feedback suppression.

  1983cited by this paper
• Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production.

  1983cited by this paper
• Migration of human helper/inducer T cells in response to supernatants from Con A-stimulated suppressor/cytotoxic T cells.

  1983cited by this paper
• Suppressor cells in melanoma and lung cancer: correlation with the clinical stage.

  1983cited by this paper
• Suppressor mechanisms in tumor immunity

  1983cited by this paper
• Production of a human T lymphocyte chemotactic factor by T cell subpopulations.

  1983cited by this paper
• Emergence of low‐mobility t lymphocytes in cancer patients and its clinical significance

  1983cited by this paper
• Functional characteristics of histamine receptor-bearing mononuclear cells. I. Selective production of lymphocyte chemoattractant lymphokines with histamine used as a ligand.

  1983cited by this paper
• The mechanism of inhibition of human IL 2 production.

  1982cited by this paper
• Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses.

  1981cited by this paper
• Human blood T lymphocytes that suppress the mixed leukocyte culture reactivity of lymphocytes from HLA-B14 bearing individuals.

  1979cited by this paper
• Prostaglandin-producing suppressor cells in Hodgkin's disease.

  1977cited by this paper
• Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts.

  1976cited by this paper
• An inhibitor of macrophage chemotaxis produced by neoplasms.

  1976cited by this paper
• Delayed-Hypersensitivity Reactions in Patients with Cancer

  1974cited by this paper
• Activation of suppressor T cells by tumour cells and specific antibody

  1974cited by this paper
• Abnormal monocyte chemotactic response in cancer patients.

  1974cited by this paper
• The delayed hypersensitivity reaction in breast cancer

  1974cited by this paper
• Impaired immunologic reactivity and recurrence following cancer surgery

  1970cited by this paper
• Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens.

  1969cited by this paper
• Prolonged skin homograft survival in advanced cancer and cirrhosis of the liver.

  1962cited by this paper
• Survival of skin homografts in terminal cancer patients.

  1962cited by this paper

• Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice

  2005cites this paper
• Enhanced immunosuppressive activity associated with metastatic lymphoma cells.

  1993cites this paper
• In vitro models of lymphocyte transendothelial migration.

  1992cites this paper
• Lymphocyte recruitment to the lung.

  1990cites this paper
• Immunosuppression by Metastatic Tumors

  1989cites this paper
• Lymphocyte motility and lymphocyte chemoattractant factors.

  1988cites this paper
• Prognostic value of assays of immune competency

  1987cites this paper
• Lymphocyte locomotion "in vitro": the role of growth activators and chemoattractants.

  1987cites this paper